Nalaganje...
Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐...
Shranjeno v:
| izdano v: | Pharmacol Res Perspect |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8135083/ https://ncbi.nlm.nih.gov/pubmed/34014033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.777 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|